# "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"

> **NCT02348593** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 239 (actual)

## Conditions studied

- Narcolepsy

## Interventions

- **DRUG:** JZP-110
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT02348593
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348593, ""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02348593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*